Neuren Nets $50M from Rare Disease Voucher Sale Boosting Neurological Pipeline

• Neuren receives one-third share of US$150 million Priority Review Voucher sale
• Voucher granted by FDA after approval of DAYBUE™ for Rett syndrome
• Proceeds provide substantial capital boost for Neuren’s drug development
• Neuren’s NNZ-2591 advancing with positive Phase 2 clinical trial results